Clinical Trials Logo

Neuroendocrine Tumors clinical trials

View clinical trials related to Neuroendocrine Tumors.

Filter by:

NCT ID: NCT03290079 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas

Start date: November 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to: - Assess overall radiographic response rate (ORR) - Assess progression-free survival (PFS) - Test the safety and tolerability of Pembrolizumab

NCT ID: NCT03289741 Recruiting - Clinical trials for Neuroendocrine Tumors

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Start date: September 19, 2017
Phase: Phase 4
Study type: Interventional

This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.

NCT ID: NCT03288597 Recruiting - Clinical trials for Neuroendocrine Tumors

Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms

Start date: September 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

68Ga-DOTANOC and 18F-FDG PET/CT have important values in the staging and clinical treatment of neuroendocrine tumors. Retrospective studies suggest that the positivite rates and SUVmax of dual imaging associated with pathological findings and prognosis. The study was designed to confirm thet clinical values of dual imagings for neuroendocrine tumors.

NCT ID: NCT03288402 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients

DIB-NET
Start date: January 2017
Phase: N/A
Study type: Interventional

Measurement of plasma chromogranin A remains the most commonly used biomarkers for both screening and monitoring of patients with gastro-entero-pancreatic neuroendocrine tumours (GEP-NET), despite several limitations that include: lack of a reference CgA standard; wide variations depending on the used assay in different laboratories; and varying sensitivity ranges from 60 to 90% with low specificity <50%, depending on the population studied (Oberg et al. Endocrine Connections 2016). Surprisingly, and to the best of our knowledge, only three studies with small numbers of participants have been published that have investigated possible effects of food intake on the measurement of CgA. Most have been performed in healthy controls or patients on treatment with proton pump inhibitors for chronic gastritis (up to n = 11 per group) but only one study has investigated patients with GEP-NET, where n = 6 patients with gastric NET were included. In this study, the investigators aim to assess the time dependent effects of normally ingested diet (5-item English breakfast; or tea or coffee; or ongoing fasted state) on plasma chromogranin A measurements, using timed measurements over 180 min following an > 10 hours overnight fast, in a randomised double-crossover design. The investigators aimed to include 25 - 35 patients with a histologically confirmed diagnosis of a GEP-NET of varying primary tumour location, tumour stage, grade; and presence or absence of treatment with long acting somatostatin analogues; as well as 10 - 15 healthy controls. In an additional small subgroup of patients who are initiated on treatment with GLP-1 analogues i.e. for type 2 diabetes or obesity, the investigators aim to establish whether injection of GLP-1 analogues has any effects on plasma CgA measurements.

NCT ID: NCT03279601 Recruiting - Clinical trials for Neuroendocrine Tumors

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

Start date: September 1, 2017
Phase: Phase 2
Study type: Interventional

The study will be conducted to compare the safety and efficacy of Capecitabine Combined With Dacarbazine(CAPDTIC) and Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal neuroendocrine tumor.In this prospective randomized phase II study, the investigators aim to compare the survival benefit as well as the safety forCapecitabine Combined With Dacarbazine(CAPDTIC) versus Capecitabine Combined Temozolomide(CAPTEM) in advanced or metastatic gastrointestinal pancreatic and esophageal neuroendocrine tumor.

NCT ID: NCT03278379 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

Avelumab in G2-3 NET

NET-002
Start date: September 20, 2017
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm, open-label, phase II trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 2-3, well-differentiated neuroendocrine.tumour.

NCT ID: NCT03278275 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105

Start date: October 1, 2017
Phase: Phase 2
Study type: Interventional

The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of uPAR PET/CT with the radioligand 68Ga-NOTA-AE105 in patients with neuroendocrine tumors (NETs).

NCT ID: NCT03273712 Recruiting - Neuroblastoma Clinical Trials

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

Start date: September 29, 2017
Phase: Phase 2
Study type: Interventional

This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.

NCT ID: NCT03271281 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2

Start date: October 23, 2017
Phase: Phase 2
Study type: Interventional

The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/CT with the radioligand 68Ga-NODAGA- E[c(RGDyK)]2 in patients with neuroendocrine tumors (NETs).

NCT ID: NCT03220217 Recruiting - Clinical trials for Gastro-Enteropancreatic Neuroendocrine Tumor

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Start date: September 20, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research is to define the optimal dose of 68Ga-OPS202 as a PET imaging agent to be used to detect and localize gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). 68Ga-OPS202 is a radiolabelled imaging agent to be used in association with Positron-Emission-Tomography (PET). 68Ga-OPS202 is made of two main components: 1) OPS202, an antagonistic somatostatin analogue which binds to the somatostatin receptor (type 2) present on the surface of the tumor cells and 2) Gallium 68, a radioisotope that combined with OPS202 can be seen in the PET scanner.